All - I didn't get a single response to my posting last week
(https://www.jiscmail.ac.uk/cgi-bin/webadmin?A2=ind0812&L=CCP4BB&T=0&O=D
&X=512817322E87355F7F&Y=i.tickle%40astex-therapeutics.com&P=266420)
concerning the formulae that are widely used for the 'minimally-biased'
Fourier and difference Fourier coefficients. It probably didn't help
that I posted it in the middle of the festive season! - but still
somewhat surprising since I imagine everyone here is involved with maps
at one time or another, and has an interest in getting the density that
shows best what if any further modifications need to be made to the
current model. Anyway now that people have hopefully returned to work
from the rigours of the CCP4 Study Weekend I thought I'd post it again
and see if I can provoke some discussion this time. I won't post all my
calculations again, just a summary of my conclusions.
First, I think I can now prove my conjecture that the optimal difference
Fourier coefficient dF is given for both acentrics and centrics by:
dF = Fm - DFc
where Fm is the 'minimally-biased' Fourier coefficient derived by Read
(AC 1986,A42,140):
Fm(acen) = 2mFo - DFc
Fm(cen) = mFo
I'm satisfied now that my alternative conjecture, that dF = Fm - Fc, is
probably wrong. Also I can see that there might be an argument to put
DFc in the FC (FC_ALL) column in place of Fc as appears to be currently
done by REFMAC, but not by SIGMAA (but I'd still like to see some
discussion of that).
So here's a summary comparison of theory with what is my understanding
is actually implemented in software, and with the inconsistencies
highlighted (>...<):
Source Coefficient Acentrics Centrics
====== =========== ========= ========
THEORY(Read) Fm 2mFo - DFc mFo
.. (me) dF 2(mFo-DFc) mFo - DFc
SIGMAA Fm 2mFo - DFc mFo
dF > mFo - DFc < mFo - DFc
Fc Fc Fc
REFMAC Fm 2mFo - DFc > 2mFo - DFc <
dF > mFo - DFc < mFo - DFc
Fc > DFc < > DFc <
Even if you don't accept my suggestion for the acentric dF coefficient
there are clearly some significant inconsistencies between the
coefficients output by SIGMAA & REFMAC which it would be nice to
resolve!
Cheers
-- Ian
Disclaimer
This communication is confidential and may contain privileged information
intended solely for the named addressee(s). It may not be used or disclosed
except for the purpose for which it has been sent. If you are not the intended
recipient you must not review, use, disclose, copy, distribute or take any
action in reliance upon it. If you have received this communication in error,
please notify Astex Therapeutics Ltd by emailing
i.tic...@astex-therapeutics.com and destroy all copies of the message and any
attached documents.
Astex Therapeutics Ltd monitors, controls and protects all its messaging
traffic in compliance with its corporate email policy. The Company accepts no
liability or responsibility for any onward transmission or use of emails and
attachments having left the Astex Therapeutics domain. Unless expressly
stated, opinions in this message are those of the individual sender and not of
Astex Therapeutics Ltd. The recipient should check this email and any
attachments for the presence of computer viruses. Astex Therapeutics Ltd
accepts no liability for damage caused by any virus transmitted by this email.
E-mail is susceptible to data corruption, interception, unauthorized amendment,
and tampering, Astex Therapeutics Ltd only send and receive e-mails on the
basis that the Company is not liable for any such alteration or any
consequences thereof.
Astex Therapeutics Ltd., Registered in England at 436 Cambridge Science Park,
Cambridge CB4 0QA under number 3751674
